Could inflammatory bowel disease and colon cancer be prevented by changing the shape of a single protein?
There is an intimate link between uncontrolled inflammation in the gut associated with inflammatory bowel disease and the eventual development of colon cancer. This uncontrolled inflammation is associated with changes in bacteria populations in the gut, which can invade the mucosal tissue after damage to the protective cellular barrier lining the tissue.
But Virginia Tech researchers found that modifying the shape of IRAK-M, a protein that controls inflammation, can significantly reduce the clinical progression of both diseases in pre-clinical animal models.
The altered protein causes the immune system to become supercharged, clearing out the bacteria before they can do any damage. The team’s findings were published in eBioMedicine.
“When we tested mice with the altered IRAK-M protein, they had less inflammation overall and remarkably less cancer,” said Coy Allen, an assistant professor of inflammatory disease in the Department of Biomedical Sciences and Pathobiology in the Virginia-Maryland College of Veterinary Medicine and a Fralin Life Science Institute affiliate.
The next step, he said, will be to evaluate these findings in human patients through ongoing collaborations with Carilion Clinic and Duke University.
The team is also evaluating their findings in laboratory-assembled “mini-guts” — live tissue models that Allen and his team assembled by growing intestinal stem cells on petri dishes to form highly complex small intestinal and colon tissue.
“Ultimately, if we can design therapeutics to target IRAK-M, we think it could be a viable strategy for preventing inflammatory bowel disease and cancer,” said Allen.
Colon cancer is the second leading cause of cancer-related deaths in the United States and the third most common cancer in men and women, according to the Centers for Disease Control and Prevention.
More than 10 Virginia Tech faculty members and students are working on the project, including co-principal investigator Liwu Li, a professor of biological sciences in the College of Science; Clay Caswell, an assistant professor of bacteriology in the veterinary college; Rich Helm, an associate professor of biochemistry in the College of Agriculture and Life Sciences; Dan Slade, an assistant professor of biochemistry in the College of Agriculture and Life Sciences; and Tanya LeRoith, a clinical associate professor of anatomic pathology in the veterinary college.
Daniel Rothschild, of Nevada City, California, currently in the combined Ph.D./D.V.M program in the veterinary college, is working in Allen’s lab, and was first author on the paper.
“Working on this project alongside Dr. Allen and our fellow collaborators has personally been a great experience,” said Rothschild. “It’s really exciting when your findings have the potential for clinical implications that can be applied to help patients. From a scientist’s perspective, that’s what it’s all about, and hopefully our findings provide a good avenue for development of future therapeutics to treat maladies, such as inflammatory bowel disease and colon cancer.”